# Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone

> **NCT00041626** · PHASE3 · UNKNOWN · sponsor: **Introgen Therapeutics**

## Conditions studied

- Carcinoma, Squamous Cell

## Interventions

- **GENETIC:** INGN 201

## Key facts

- **NCT ID:** NCT00041626
- **Lead sponsor:** Introgen Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2007-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00041626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00041626, "Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00041626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*